Comparative Pharmacology
Head-to-head clinical analysis: SULTRIN versus THIOSULFIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SULTRIN versus THIOSULFIL.
SULTRIN vs THIOSULFIL
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Sultrin (sulfanilamide, sulfathiazole, sulfacetamide) is a triple sulfonamide combination that acts as a bacteriostatic agent. It inhibits bacterial folic acid synthesis by competing with para-aminobenzoic acid (PABA) for the active site of dihydropteroate synthase, thereby blocking the conversion of PABA to dihydrofolic acid. This disrupts nucleic acid synthesis in susceptible bacteria.
Thiosulfil (sulfamethizole) is a sulfonamide antibiotic that inhibits bacterial dihydropteroate synthase, blocking folic acid synthesis and thereby nucleic acid production.
Vaginitis due to Haemophilus vaginalis (now Gardnerella vaginalis) – FDA approvedTreatment of bacterial vaginosis (off-label in some regions)
Urinary tract infectionsProphylaxis of rheumatic feverNocardiosisToxoplasmosis
Intravaginal administration: one applicatorful (approximately 5 g) of Sultrin Triple Sulfa Cream (containing sulfathiazole, sulfacetamide, and sulfabenzamide) intravaginally once or twice daily for 4 to 7 days. Oral: Not applicable.
500 mg orally twice daily for 10-14 days.
None Documented
None Documented
Terminal half-life 8-12 hours; requires dose adjustment in renal impairment (CrCl <30 mL/min)
Terminal elimination half-life is 2-4 hours in patients with normal renal function (creatinine clearance >80 mL/min); prolonged to 20-50 hours in severe renal impairment (CrCl <30 mL/min).
Sulfonamides are primarily metabolized in the liver via acetylation (N-acetyltransferase) and glucuronidation. The acetylated metabolites are inactive but may crystallize in urine at high concentrations.
Primarily hepatic metabolism via acetylation and glucuronidation; excreted renally as unchanged drug and metabolites.
Renal: ~70% unchanged; biliary/fecal: ~30% as metabolites
Renal: 70-90% as unchanged drug via glomerular filtration and tubular secretion. Biliary/fecal: <5%.
65% bound to albumin
85-90% bound to serum albumin.
0.3 L/kg; indicates distribution primarily into extracellular fluid
0.2-0.4 L/kg, indicating distribution primarily in extracellular fluid and low tissue penetration.
Oral: 90% (first-pass metabolism minimal); IM: 100%
Oral: 85-95% (well absorbed from gastrointestinal tract).
Contraindicated in patients with significant renal impairment (e.g., GFR <30 mL/min/1.73 m²) due to risk of sulfonamide accumulation and toxicity. No specific dose adjustment guidelines available; use is not recommended.
GFR 30-50 mL/min: 500 mg every 24-36 hours; GFR 10-29 mL/min: 500 mg every 36-48 hours; GFR <10 mL/min: 500 mg every 48-72 hours or consider alternative.
No specific guidelines for Child-Pugh classification. Use with caution in severe hepatic impairment due to potential sulfonamide metabolism alterations. Monitor for signs of toxicity.
Child-Pugh A: no adjustment; Child-Pugh B: 250 mg orally twice daily; Child-Pugh C: not recommended.
Safety and efficacy in pediatric patients have not been established. Not recommended for use in children.
For children >2 months: 25-50 mg/kg/day orally divided every 12 hours; maximum 4 g/day. For infants <2 months: not recommended.
Use with caution in elderly patients due to age-related renal function decline. Monitor renal function and for adverse reactions; consider alternative therapy if renal impairment is present.
Start at 250 mg orally twice daily; increase to 500 mg twice daily based on tolerance and renal function; monitor for hypersensitivity and renal impairment.
None
Sulfonamides have been associated with severe hypersensitivity reactions including Stevens-Johnson syndrome, toxic epidermal necrolysis, and hematologic toxicities. Use caution in patients with history of sulfonamide allergy.
["Risk of severe hypersensitivity reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis","Hematologic toxicity: agranulocytosis, aplastic anemia (especially with prolonged use)","Renal toxicity: crystalluria and renal tubular obstruction, particularly in dehydrated patients or those with renal impairment","Hepatic impairment: risk of hepatotoxicity and hyperbilirubinemia","Prolonged use may lead to superinfection with resistant organisms","Avoid use during pregnancy near term due to risk of kernicterus in the newborn","Cross-sensitivity with other sulfonamides and thiazide diuretics"]
Monitor for hypersensitivity reactions, hematologic effects (agranulocytosis, aplastic anemia), renal toxicity, and photosensitivity. Use cautiously in patients with renal impairment or G6PD deficiency.
["Hypersensitivity to sulfonamides or any component of the formulation","Porphyria (sulfonamides may precipitate acute attacks)","Significant renal or hepatic impairment","Pregnancy at term","Lactation (sulfonamides are excreted in breast milk and may cause kernicterus in nursing infants)"]
Hypersensitivity to sulfonamides, severe renal or hepatic impairment, porphyria, pregnancy (especially near term), and lactation.
Data Pending Review
Data Pending Review
No clinically significant food interactions. No dietary restrictions required.
Avoid acidic foods and beverages (e.g., cranberry juice, citrus) as they may increase risk of crystalluria. Maintain adequate hydration. No significant food-drug interactions reported aside from the need for alkalinization of urine to prevent crystallization. Avoid alcohol as it may increase risk of side effects.
Sultrin (sulfanilamide) is a sulfonamide antimicrobial. First trimester: Crosses placenta, potential for teratogenicity (cleft palate, cardiovascular defects) based on animal studies; human data insufficient. Second and third trimesters: Risk of kernicterus in neonates due to bilirubin displacement if administered near term. Contraindicated after 32 weeks gestation.
Pregnancy category D. Sulfonamides cross the placenta and may cause kernicterus in the newborn if used near term. Avoid use in first and third trimesters; second trimester use only if clearly needed.
Sulfanilamide is excreted into breast milk. M/P ratio unknown. Use caution in breastfeeding, especially in infants with hyperbilirubinemia or G6PD deficiency, due to risk of kernicterus or hemolytic anemia. Alternative agents preferred.
Excreted in breast milk in low amounts. M/P ratio not established. Caution in infants with hyperbilirubinemia or G6PD deficiency. American Academy of Pediatrics considers compatible with breastfeeding.
No standard dosing adjustments recommended for pregnancy. However, because of increased renal clearance during pregnancy, consider monitoring therapeutic efficacy. Avoid use near delivery; discontinue at least 2 weeks before expected due date.
No dose adjustment required for pregnancy; however, avoid use during term due to risk of kernicterus.
Category C
Category C
SULTRIN (sulfacetamide sodium 10%, sulfur 5%) is a topical sulfonamide with keratolytic activity. Effective for acne vulgaris and seborrheic dermatitis. Avoid use in patients with known sulfonamide hypersensitivity. Reassess if no improvement after 8-12 weeks. Use caution in renal impairment due to potential systemic absorption. May stain clothing and jewelry.
THIOSULFIL (sulfamethizole) is a short-acting sulfonamide used primarily for urinary tract infections. Obtain baseline renal and hepatic function. Ensure adequate fluid intake (≥2 L/day) to prevent crystalluria. Monitor for hypersensitivity reactions, especially in patients with sulfa allergies. Note that sulfamethizole may potentiate the effects of warfarin, oral hypoglycemics, and methotrexate. Use with caution in G6PD deficiency due to risk of hemolytic anemia.
Apply a thin layer to affected areas once or twice daily as directed.Avoid contact with eyes, mouth, and mucous membranes.May cause temporary stinging or burning upon application.Do not use if allergic to sulfa drugs or sulfur.Discontinue and inform doctor if skin rash or irritation develops.Antibacterial activity may be reduced by concomitant use of other topical products containing heavy metals (e.g., mercury, silver).
Take this medication exactly as prescribed, with a full glass of water.Drink plenty of fluids (at least 8 glasses per day) to prevent kidney stones.Complete the full course even if you feel better to prevent antibiotic resistance.Avoid prolonged sun exposure; use sunscreen as this drug can increase photosensitivity.Report any rash, fever, sore throat, unusual bleeding, or yellowing of skin/eyes immediately.Inform your doctor if you are pregnant, planning to become pregnant, or breastfeeding.This medication may cause dizziness; avoid driving until you know how it affects you.Do not take with antacids containing magnesium trisilicate as they reduce absorption.